➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Dow
Express Scripts
Merck
Baxter

Last Updated: May 29, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Coenzyme A


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Coenzyme A?

Coenzyme A is an investigational drug.

There have been 4 clinical trials for Coenzyme A. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2010.

The most common disease conditions in clinical trials are Hyperlipoproteinemias, Hyperlipidemias, and [disabled in preview]. The leading clinical trial sponsors are Zhejiang University and [disabled in preview].

There are two US patents protecting this investigational drug and twenty-three international patents.

Recent Clinical Trials for Coenzyme A
TitleSponsorPhase
The Effects of Coenzyme A Combined With Statin on Serum Lipids in Patients With HyperlipidemiaZhejiang UniversityPhase 2/Phase 3
Comparison of Coenzyme A and Pantethine Capsule for Safety and Efficacy On Patients With HyperlipidemiaZhejiang UniversityPhase 3
Comparison of Coenzyme A and Fenofibrate for Safety and Efficacy On Patients With HyperlipidemiaZhejiang UniversityPhase 3

See all Coenzyme A clinical trials

Clinical Trial Summary for Coenzyme A

Top disease conditions for Coenzyme A
Top clinical trial sponsors for Coenzyme A

See all Coenzyme A clinical trials

US Patents for Coenzyme A

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Coenzyme A   Start Trial Methods of expressing products in mammalian cells INTREXON CEU, INC. (Blacksburg, VA)   Start Trial
Coenzyme A   Start Trial Variety corn line GAQ2025 Syngenta Participations AG (Basel, CH)   Start Trial
Coenzyme A   Start Trial Peptide vaccines against PCSK9 AFFIRIS AG (Vienna, AT)   Start Trial
Coenzyme A   Start Trial Compounds useful for the treatment of metabolic disorders and synthesis of the same North Carolina Central University (Durham, NC) The University of North Carolina at Chapel Hill (Chapel Hill, NC)   Start Trial
Coenzyme A   Start Trial Protein kinase C inhibitors and uses thereof Rigel Pharmaceuticals, Inc. (South San Francisco, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Coenzyme A

Drugname Country Document Number Estimated Expiration Related US Patent
Coenzyme A World Intellectual Property Organization (WIPO) 2012027533 2030-08-25   Start Trial
Coenzyme A Canada 2947084 2035-11-13   Start Trial
Coenzyme A Australia 2015222283 2034-02-28   Start Trial
Coenzyme A Brazil 112016019389 2034-02-28   Start Trial
Coenzyme A Canada 2940315 2034-02-28   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Baxter
AstraZeneca
McKesson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.